Drug Trial Radar · NCT02481440
Repeated Subarachnoid Administrations of hUC-MSCs in Treating SCI
Last checked: Nov 19, 2026Latest source record: Jun 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Mar 30, 2018
Primary completion
Mar 31, 2020
Study completion Mar 31, 2020
Sponsor
- Lead sponsor
- Limin RongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of repeated intrathecal administrations of allogeneic human umbilical cord mesenchymal stem cells for the treatment of spinal cord injury.
Conditions
- Spinal Cord Injuries
Interventions
human umbilical cord mesenchymal stem cells (hUC-MSCs)Biological
Four times of intrathecal administrations of hUC-MSCs
Primary outcomes
What the sponsor says the trial is designed to measure.
- American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-upTime frame: at 12 months following the final administration of hUC-MSCs
- SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score at the Fourth Follow-upTime frame: at 12 months following the final administration of hUC-MSCs
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.